The World Health Organization released its first global guidelines on 7 October 2026, advising diet, exercise, and counseling over popular weight-loss drugs for children and adolescents facing rising obesity rates, while warning that current evidence on GLP-1 medications remains insufficient for younger patients.
WHO Issues First Obesity Guidelines For Youth
The World Health Organization launched two new guidelines on 7 October 2026, establishing a framework for health workers and systems to deliver timely, evidence-based and people-centered obesity care for children and adolescents (Reuters).
Statistical tracking shows that roughly 400 million people aged 5 to 19 were overweight in 2024, with 170 million of them living with obesity. According to UNICEF data (Reuters), obesity has surpassed undernutrition as the most prevalent form of malnutrition among school-aged children and adolescents globally. The prevalence of obesity within this demographic has quadrupled since 1990.
Age Restrictions on Drugs and Surgery
For children under the age of 10, the health agency strongly endorsed tailored diets, physical activity, and combined behavioral support (Reuters).
The organization explicitly ruled out obesity medications, surgery, and medical devices for this younger group, citing persistent doubts regarding their long-term effectiveness and safety (Reuters). For adolescents aged 10 to 19, weight-loss drugs may be considered, but only after supervised interventions have failed (Reuters).
Bariatric surgery remains an option exclusively for physically and mentally mature adolescents suffering from severe obesity, and only after six months of unsuccessful treatment (Reuters).
Regional Approvals Contrast With Limited Data
Novo Nordisk products Wegovy and Saxenda are authorized for certain adolescents aged 12 and older in the United States and the European Union, while EU regulators also permit Saxenda usage for children between six and 11 (Reuters). Some pharmaceutical treatments are already cleared for younger patients in specific regions.
Despite these regional authorizations, Luz María De Regil, director of the Department of Nutrition and Food Safety, noted that current data on GLP-1 drugs remains limited (Reuters). Researchers continue to monitor ongoing efficacy and safety trials, leaving open the possibility of future guideline revisions as new evidence appears (Reuters).
To support these efforts, the agency recommended tailored diets, physical activity, and behavioral programs involving caregivers, noting that supervised digital support can serve as an optional tool (Reuters). Healthy diets and physical activity must remain accessible and affordable because treatment alone cannot halt the ongoing rise in global obesity (Reuters).
